GLP-1 and Hyperoxia for Organ Protection in Heart Surgery "GLORIOUS"


Phase N/A Results N/A

Summary of Purpose

Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during weaning from cardio-pulmonary bypass.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 April 2018.

1 Feb 2016 6 Dec 2015 1 Jan 2020 1 Jan 2020 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Factorial Assignment